Pfizer, Inc.

PFE

US7170811035

Pharmaceuticals

Market Closed - Nyse Other stock markets 21:01:20 16/07/2024 BST			Pre-market 00:00:10
29.5 ^USD	+1.37%		29.5	0.00%

07-15	Everest Medicines Announces Positive Topline Results from Maintenance Period of Etrasimod Phase 3 Clinical Trial Conducted in Asia for the Treatment of Moderately-to-Severely Active Ulcerative Colitis	CI
07-12	Health Care Up as Momentum Builds -- Health Care Roundup	DJ

Biontech, Pfizer Say There Is No Data To Demonstrate That Protection Against Covid-19 From Their Vaccine Is Sustained Beyond 21 Days After First Dose

January 04, 2021 at 04:39 pm

BIONTECH, PFIZER SAY THERE IS NO DATA TO DEMONSTRATE THAT PROTECTION AGAINST COVID-19 FROM THEIR VACCINE IS SUSTAINED BEYOND 21 DAYS AFTER FIRST DOSE

Latest news about Pfizer, Inc.

Everest Medicines Announces Positive Topline Results from Maintenance Period of Etrasimod Phase 3 Clinical Trial Conducted in Asia for the Treatment of Moderately-to-Severely Active Ulcerative Colitis	07-15	CI
Health Care Up as Momentum Builds -- Health Care Roundup	07-12	DJ
UBS Raises Price Target on Pfizer to $30 From $28, Maintains Neutral Rating	07-12	MT
PFIZER INC : Receives a Buy rating from Goldman Sachs	07-12	ZD
Health Care Up as Obesity-Drug Wars Continue -- Health Care Roundup	07-11	DJ
Sector Update: Health Care Stocks Rise Late Afternoon	07-11	MT
PFIZER INC : Jefferies keeps its Buy rating	07-11	ZD
Sector Update: Health Care Stocks Advance in Afternoon Trading	07-11	MT
Top Midday Stories: Bain Capital to Acquire Envestnet; Delta, Pepsi Report Q2 Earnings; Pfizer Advances Development of Weight-Loss Pill; DOE Pledges $1.7 Billion for EV	07-11	MT
Sector Update: Health Care Stocks Advance Premarket Thursday	07-11	MT
Sector Update: Health Care	07-11	MT
CureVac Notes New Court Trial Timeline for Patent Cases Against Pfizer, BioNTech	07-11	MT
Pfizer: advances in anti-obesity pill danuglipron	07-11	CF
CureVac Provides Trial Dates for Patent Litigation Against Pfizer, BioNTech	07-11	MT
Exchange-Traded Funds, Equity Futures Edge Lower Pre-Bell Ahead of Key Inflation Data	07-11	MT
Pfizer to Advance Development of Modified-Release Formulation of Danuglipron	07-11	MT
Futures edge lower ahead of inflation test; Delta Airlines falls	07-11	RE
Pfizer Picks Once-Daily Obesity Pill Version for Further Study	07-11	DJ
Pfizer moves forward with once-daily weight loss drug	07-11	RE
Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron	07-11	CI
Pfizer: collaboration agreement with Evotec in France	07-10	CF
Barclays Adjusts Pfizer's Price Target to $30 From $28	07-10	MT
Sector Update: Health Care Stocks Steady Premarket Wednesday	07-10	MT
Evotec, Pfizer Enter Research Collaboration on Metabolic, Infectious Diseases	07-10	MT
Evotec, Pfizer Team Up for Early Drug Discovery for Metabolic, infectious Diseases	07-10	MT

Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (72.8%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (13.8%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (12.1%); - other (1.3%). At the end of 2022, the group had more than 35 manufacturing sites worldwide. Net sales are distributed geographically as follows: the United States (42.3%), Europe (21.9%) and other (35.8%).

Sector

Pharmaceuticals

Calendar

25/07/2024 - Détachement de

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Pfizer, Inc: A cycle for nothing?

December 14, 2023 at 03:58 pm

Albert Bourla, Pfizer CEO (full interview): mRNA, acquisitions, weight-loss drugs

October 31, 2023 at 08:50 pm

More Strategies

Ratings for Pfizer, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

29.1 USD

Average target price

32.1 USD

Spread / Average Target

+10.30%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PFIZER, INC.	+2.47%	165B
ELI LILLY AND COMPANY	+61.53%	856B
NOVO NORDISK A/S	+38.95%	631B
JOHNSON & JOHNSON	-3.66%	359B
MERCK & CO., INC.	+15.06%	325B
ABBVIE INC.	+9.18%	297B
ROCHE HOLDING AG	+5.89%	234B
NOVARTIS AG	+16.53%	226B
AMGEN INC.	+15.67%	177B
SANOFI	+2.41%	126B

Other Pharmaceuticals

Pfizer, Inc.

Equities

PFE

US7170811035

Pharmaceuticals

Biontech, Pfizer Say There Is No Data To Demonstrate That Protection Against Covid-19 From Their Vaccine Is Sustained Beyond 21 Days After First Dose

Latest news about Pfizer, Inc.

Chart Pfizer, Inc.

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Pfizer, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals